PRESS RELEASE
20 November 2026 13:00:00 CET

Cereno Scientific

Cereno Scientific invites shareholders and investors to a digital investor meeting and Q&A

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech company pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, invites shareholders, investors and other interested parties to a digital investor meeting on Friday, November 27, 2026. The meeting follows the announcement of the intended rights issue and will focus on the Company's financing and priorities going forward.

On November 12, 2026, Cereno Scientific announced its intention to carry out a rights issue of units totaling approximately SEK 400 million. The announcement has raised questions and concerns among shareholders, which the Company wishes to address and clarify.

In response to requests for further information and dialogue, Cereno Scientific is hosting a digital investor meeting dedicated primarily to answering questions from shareholders and investors. Following a brief introduction by the Company, an external moderator will lead the Q&A session.

Shareholders and other interested parties are encouraged to submit questions in advance. Questions will be grouped by topic and addressed during the meeting, with a focus on the planned rights issue, the Company's financial position and its plans going forward.

Sten R. Sörensen, CEO of Cereno Scientific, comments:"We want to give our shareholders a clearer understanding of the planned financing, how the proceeds will be used and our priorities going forward. The meeting provides an opportunity to explain the rationale behind the proposal in greater detail and answer shareholders' questions. We value our shareholders' engagement and welcome questions both ahead of and during the meeting."

Meeting details

Date: Friday, November 27, 2026
Time: 12:00 CET
Meeting link: https://www.youtube.com/live/TrJ6mJAm1Qw
Submit questions to: fraga@investorstudios.se
Deadline for submitting questions: November 25, 2026

The meeting is open to shareholders, investors and other interested parties. A recording of the meeting, together with a summary of the questions and answers, will be made available on the Company's website, www.cerenoscientific.com, following the meeting.

For further information, please contact:
Tove Bergenholt, Head of IR & Communications
Email: tove.bergenholt@cerenoscientific.com
Phone: +46 73- 236 62 46

Cereno Scientific

About Cereno Scientific AB
Cereno Scientific is pioneering treatments to enhance and extend life. The company's innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the underlying mechanisms of pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function, functional class, risk score and patient quality of life, with early signs consistent with reverse vascular remodeling. An Expanded Access Program confirmed CS1 to be well-tolerated with a favorable safety profile over 12 months of treatment and showed that a majority of patients completing treatment maintained or improved clinical status. CS1 is currently being evaluated in EPIMODE, a global, placebo-controlled Phase IIb trial in PAH. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of a range of cardiovascular and pulmonary diseases with high unmet needs. CS014 showed a favorable safety and tolerability profile in Phase I, and is being advanced through a streamlined, FDA-aligned pathway toward Phase IIb in pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also advancing the preclinical program CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist shown to prevent thrombosis without increased bleeding risk, currently being evaluated in antiphospholipid syndrome (APS).

The Company is headquartered in GoCo Health Innovation City in Gothenburg, Sweden, and has a US subsidiary, Cereno Scientific Inc., located in Kendall Square, Boston. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB Carnegie Investment Bank AB, **certifiedadviser@carnegie.se**. More information can be found on **www.cerenoscientific.com**.